MDGL - MADRIGAL PHARMACEUTICALS, INC.
IEX Last Trade
312.13
0.690 0.221%
Share volume: 4,322
Last Updated: Thu 26 Dec 2024 08:30:01 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$311.44
0.69
0.22%
Fundamental analysis
21%
Profitability
25%
Dept financing
2%
Liquidity
50%
Performance
15%
Performance
5 Days
0.36%
1 Month
-7.35%
3 Months
45.86%
6 Months
13.31%
1 Year
32.02%
2 Year
14.05%
Key data
Stock price
$312.13
DAY RANGE
$308.89 - $314.65
52 WEEK RANGE
$189.98 - $368.29
52 WEEK CHANGE
$33.34
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Paul A. Friedman
Region: US
Website: madrigalpharma.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: madrigalpharma.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Madrigal Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the. treatment of non-alcoholic steatohepatitis.
Recent news